June 28, 2006 -- Novartis received FDA approval of Exelon as a therapy for dementia associated with Parkinson’s disease; Replidyne priced its IPO at $10 per share, down from the $14/$16 range; Affymax signed a $535 million deal with Takeda Pharma for Hematide, an anemia drug; King Pharma entered a partnership with Depomedto market Glumetza, a diabetes drug; EntreMed won orphan drug designation for brain cancer drug Panzem; CoTherix paid $8.5 million to in-license Fasudil, a drug for pulmonary arterial hypertension; Oscient Pharma said the FDA will review Factive, an antibiotic, on September 12, 2006; Exelisis moved XL880 into a Phase II test against kidney cancer; and Cypress Bioscience will discontinue development of mirtazapine as a treatment for obstructive sleep apnea. The Centient Biotech 200™ rose 3 points to 3525.28, a rise of .08%. More details...
